» Articles » PMID: 24371652

Prolonged Response of Relapsed High Grade Serous Ovarian Carcinoma to the Oral Angiokinase Inhibitor Nintedanib in a Patient with a Germline BRCA1 Mutation

Overview
Publisher Elsevier
Date 2013 Dec 28
PMID 24371652
Authors
Affiliations
Soon will be listed here.
Abstract

► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.

References
1.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

2.
Tarnowski B, Chudecka-Glaz A, Gorski B, Rzepka-Gorska I . Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3):287-8. DOI: 10.1007/s10549-004-0779-0. View

3.
Ledermann J, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I . Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011; 29(28):3798-804. DOI: 10.1200/JCO.2010.33.5208. View

4.
Kang H, Kim H, Rih J, Mattson T, Kim K, Cho C . BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006; 281(19):13047-13056. DOI: 10.1074/jbc.M513033200. View

5.
Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View